Can a booster shot stop whooping cough bacteria in its tracks?
NCT ID NCT06903221
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a booster dose of the acellular pertussis vaccine (Tdap-IPV) can reduce the amount of whooping cough bacteria in the nose after intentional exposure. Healthy adults who were vaccinated as children will receive either the Tdap-IPV booster or a control vaccine, then be exposed to the bacteria via nasal drops. Researchers will track who gets colonized and for how long, aiming to understand how well the vaccine prevents infection and spread.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- acellular pertussis vaccine (Tdap-IPV)
- What this could lead to
- If successful, this could show that the vaccine reduces how much pertussis bacteria lives in the nose, which may help control its spread.
- What could go wrong
- This is a small, early-phase study in healthy adults, not patients. It uses a controlled infection model, so results may not reflect real-world conditions or lead to immediate changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERTUSSIS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
RadboudUMC
Nijmegen, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.